Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke

NCT00331721 is registered in ClinicalTrials.gov with PAION Deutschland GmbH as lead sponsor.

NCT NCT00331721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00331721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke
Lead sponsor
PAION Deutschland GmbH
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2006
Completion date
May 31, 2009
Enrollment
24 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

stroke